The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...
Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 - - Advancement reflects continued execution of ...
Karnataka government launched 'Kusuma Sanjeevini' programme under which patients suffering from haemophilia will be provided ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results